References
- Sung J C, White C M. Pharmacologic, pharmakocinetic and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy 2000; 20: 130–139
- Pride P G, Sedman A B, Nugent C E, Mason B. Angiotensin-converting enzyme inhibitor fetopathy. J Amer Soc Nephrol 1993; 3: 1575–1582
- Yoo K H, Wolstenholme J T, Chevalier R L. Angiotensin-converting enzyme inhibition decreases growth factor expression in the neonatal rat kidney. Pediatr Res 1997; 42: 588–592
- Briggs G G, Nageotte M P. Fatal fetal outcome with the combined use of Valsartan and Atenolol. Ann Pharmacother 2001; 35: 859–861
- Rosa F W, Bosco L A, Fossum Graham C, Milstien J B, Dreis M, Creamer J. Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstet Gynecol 1989; 74: 371–374
- Hannsens M, Keirse M JNC, Vankelecom F, Van Assche F A. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991; 78: 128–135
- Tabacova S A, Kimmel C A. Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity. Reproduct Toxicol 2001; 15: 467–478
- Buttar H S. An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development. Mol Cell Biochem 1997; 176: 61–71
- Robillard J E, Gomez R A, Van Orden D, Smith F G. Comparison of the adrenal and renal responses to angiotensin II in fetal lambs and adult sheep. Circ Res 1982; 50: 140–147
- Yosipiv I V, Dipp S, Ekdahr S S. Ontogeny of somatic angiotensin-converting enzyme. Hypertension 1994; 23: 369–374
- Moore K L, Persaud T VN. The developing human. Clinically oriented embryology. 5th. WB Saunders, Philadelphia 1993
- Barr M. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994; 50: 399–409
- Saji H, Yamanaka M, Hagiwara A, Ljiri R. Losartan and fetal toxic effects. Lancet 2001; 357: 363
- Pietrement C, Malot L, Santerne B, et al. Neonatal acute renal failure secondary to maternal exposure to Telmisartan, angiotensin II receptor antagonist. J Perinatol 2003; 23: 254–255
- Chung N A, Lip G Y, Beevers D G. Angiotensin-II-recpetor inhibitors in pregnancy. Lancet 2001; 357: 1620
- Martinovic J, Benachi A, Laurent N, Daïkha-Dahmane F, Gubler M C. Fetal toxic effects and angiotensin-II-receptor antagonits. Lancet 2001; 358: 24
- Schaefer C. Angiotensin II-receptor antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res Part A Clin Mol Teratol 2003; 67: 591–594
- Chow K M, Lam C M. Angiotensin II receptor antagonist in pregnancy. J Perinatol 2004; 24: 56–57
- Berkane N, Carlier P, Verstraete L, Mathieu E, Mathieu E, Heim N, Uzan S. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res Part A Clin Mol Teratol 2004; 70: 547–549
- Spence S G, Allen H L, Cukierski M A, Manson J M, Robertson R T, Eydelloth R S. Defining the period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. Teratology 1995; 51: 367–382
- Muller P R, James A. Pregnancy with prolonged fetal exposure to an angiotensin-converting enzyme inhibitor. J Perinatol 2002; 22: 582–584